Skip to main content

Table 2 Multivariate Cox proportional-hazard analysis of the risk of death (OS) and BRCA-like CGH status in all patients, patients with triple-negative tumors only and patients with hormone receptor-positive tumors only

From: Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

 

All patients†

Patients with TN tumors‡

Patients with HR-pos tumors§

Variable

No. events/No. patients

Hazard ratio

95% CI

P value

No. events/No. patients

Hazard ratio

95% CI

P value

No. events/No. patients

Hazard ratio

95% CI

P value

pT-stage

            

pT1/pT2

65/200

1.00

  

17/44

1.00

  

48/156

1.00

  

pT3

22/37

1.93

1.16 - 3.21

0.012

10/13

2.46

1.03 - 5.88

0.043

12/24

1.71

0.88 - 3.32

0.114

Histologic grade

            

I/II

48/147

1.00

  

7/15

1.00

  

41/132

1.00

  

III

39/90

1.34

0.81 - 2.20

0.250

20/42

1.60

0.62 - 4.13

0.334

19/48

1.25

0.69 - 2.27

0.455

aCGH pattern*

            

Non-BRCA-likeCGH tumor

56/162

1.00

  

10/21

1.00

  

46/141

1.00

  

BRCA-likeCGH tumor

31/75

1.78

0.97 - 3.24

0.061

17/36

2.11

0.72 - 6.19

0.173

14/39

1.79

0.82 - 3.92

0.143

BRCA-like CGH tumor*

            

FE90C chemotherapy

25/40

1.00

  

14/20

1.00

1.00

 

11/20

1.00

  

HD-CTC chemotherapy

6/35

0.19†

0.08 - 0.48

<0.001

3/16

0.19‡

0.19‡

0.05 – 0.66

3/19

0.19§

0.05 - 0.71

0.013

Non-BRCA-like CGH tumor*

  

†Homogeneity: P = 0.004

  

‡Homogeneity: P = 0.034

  

§Homogeneity: P = 0.048

FE90C chemotherapy

30/79

1.00

5/10

1.00

25/69

1.00

HD-CTC chemotherapy

26/83

0.89†

0.52 - 1.50

5/11

5/11

1.31‡

0.37 - 4.64

0.676

21/72

0.82§

0.46 - 1.46

0.493

  1. Three separate multivariate Cox regression models were run in all patients†, in patients with TNBC‡, and in patients with HR-positive tumors§ (see top row) and an *interaction term with treatment; the first model was stratified for number of lymph nodes (4-9 vs. ≥10) and triple-negative status (ER < 10% and PR < 10% vs. other) and based on 237 patients (12 patients contributing three events were excluded due to missing values for at least one of the variables shown). For patients with TN tumors and with HR-pos tumors only, models were stratified for lymph node status only. The TN subgroup analyses were based on 57 patients (three patients contributing two events were excluded due to missing values); for the HR-pos patients analyses were based on 180 patients (seven patients contributing zero events were excluded due to missing values). Test of homogeneity of both treatment-specific hazard ratios based on an interaction term: P = 0.004 (†), P = 0.034 (‡) and, P = 0.048 (§) OS, overall survival; TN, triple-negative; HR-pos, hormone receptor-positive; pT stage, pathological tumor size; aCGH, array comparative genomic hybridization; FE90C, 5-fluorouracil-epirubicin-cyclophosphamide; HD-CTC, high-dose cyclophosphamide-thiotepa-carboplatin.